Business Description
ISIN : US9229671048
Total Employee Number:
21Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1915.64 | |||||
Equity-to-Asset | 0.99 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -6.51 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.06 | |||||
9-Day RSI | 38.57 | |||||
14-Day RSI | 41.3 | |||||
3-1 Month Momentum % | 5.98 | |||||
6-1 Month Momentum % | 126.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 70.53 | |||||
Quick Ratio | 70.53 | |||||
Cash Ratio | 70.11 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -37.55 | |||||
ROA % | -26.59 | |||||
ROIC % | -8978.18 | |||||
ROC (Joel Greenblatt) % | -23455.67 | |||||
ROCE % | -29.46 | |||||
Moat Score | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 5.06 | |||||
Price-to-Tangible-Book | 5.06 | |||||
EV-to-EBIT | -32.87 | |||||
EV-to-EBITDA | -32.87 | |||||
EV-to-FCF | -42.1 | |||||
| Price-to-Net-Current-Asset-Value | 5.06 | |||||
| Price-to-Net-Cash | 5.1 | |||||
Earnings Yield (Greenblatt) % | -3.04 | |||||
FCF Yield % | -1.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:MANE
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Veradermics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.166 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 41.3 | ||
| 14-Day ATR ($) | 5.883762 | ||
| 20-Day SMA ($) | 104.2675 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 32 - 131.2399 | ||
| Shares Outstanding (Mil) | 41.78 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Veradermics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Veradermics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 173 days | ||
| Third quarter earnings results for 2026 | 2026-11-30 | In 85 days | ||
| Guidance call for 2026 | 2026-09-10 15:20 | In 5 days | ||
| Guidance call for 2026 | 2026-09-09 15:00 | In 4 days | ||
| Wells Fargo 21st Annual Healthcare Conference | 2026-09-08 | In 2 days | ||
| General meeting for 2026 | 2026-09-07 | In 1 day | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 110.75 (-1.77%) | ||
| Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females | 2026-07-15 08:00 | 110.17 (-0.78%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 14:00 | 91.69 (-8.42%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 15:10 | 98.18 (-3.28%) |
Veradermics Inc Frequently Asked Questions
Guru Commentaries on NYSE:MANE
Veradermics, Incorporated is a dermatologist-founded, late clinical-stage biopharmaceutical company developing VDPHL01, an extended-release oral minoxidil tablet for pattern hair loss. The company reported solid Phase 3 data in male pattern hair loss, with up to 63% of male patients showing improved hair coverage compared to just 13% on placebo. If VDPHL01 receives FDA approval, it will be uniquely positioned as the first FDA-approved oral treatment in decades for a condition affecting 80 million Americans. We are optimistic about its potential in the market.
We are familiar with the hair loss market given our experience with the Veradermics IPO, a biotech company developing an extended-release pill of minoxidil, the active ingredient in hair growth treatment, Regaine. Veradermics is valued at $5.4 billion and is more advanced than Absci, which has a market capitalisation below $2 billion. We tend to agree with Eli Lilly that in a large commercial market both products can happily coexist.
Press Release
Articles on Veradermics Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
